How have ALZN shares performed in 2024?

Alzamend Neuro's stock was trading at $0.89 at the beginning of the year. Since then, ALZN stock has decreased by 16.7% and is now trading at $0.7411. View the best growth stocks for 2024 here .

Are investors shorting Alzamend Neuro?

Alzamend Neuro saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 45,300 shares, a drop of 11.5% from the March 15th total of 51,200 shares. Based on an average trading volume of 54,600 shares, the short-interest ratio is presently 0.8 days. Currently, 0.9% of the shares of the company are short sold. View Alzamend Neuro's Short Interest .

When is Alzamend Neuro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our ALZN earnings forecast .

How were Alzamend Neuro's earnings last quarter?

Alzamend Neuro, Inc. (NASDAQ:ALZN) posted its quarterly earnings results on Wednesday, September, 13th. The company reported ($0.60) earnings per share (EPS) for the quarter.

When did Alzamend Neuro's stock split?

Shares of Alzamend Neuro reverse split on the morning of Tuesday, October 31st 2023. The 1-15 reverse split was announced on Tuesday, October 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Alzamend Neuro IPO?

Alzamend Neuro (ALZN) raised $12 million in an initial public offering (IPO) on Tuesday, June 15th 2021. The company issued 2,500,000 shares at a price of $5.00 per share. Spartan Capital Securities, LLC acted as the underwriter for the IPO and -- was co-manager.

How do I buy shares of Alzamend Neuro?

Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ALZN

Alzamend Neuro (ALZN) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free ALZN Stock Alerts

$0.74

-0.11 (-12.93%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.74
▼
$0.88
50-Day Range: $0.74
▼
$1.20
52-Week Range: $0.74
▼
$11.91

Volume: 114,685 shs
Average Volume: 54,053 shs
Market Capitalization: $5.09 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Alzamend Neuro alerts:

Alzamend Neuro MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.94% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.43
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$304 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.77 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Alzamend Neuro.

5.0

Short Interest

Percentage of Shares Shorted
0.94% of the float of Alzamend Neuro has been sold short.
Short Interest Ratio / Days to Cover
Alzamend Neuro has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Alzamend Neuro has recently decreased by 11.52%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Alzamend Neuro does not currently pay a dividend.
Dividend Growth
Alzamend Neuro does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALZN.

3.0

News and Social Media Coverage

News Sentiment
Alzamend Neuro has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Alzamend Neuro this week, compared to 0 articles on an average week.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alzamend Neuro insiders have bought more of their company's stock than they have sold. Specifically, they have bought $304.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
52.22% of the stock of Alzamend Neuro is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
49.61% of the stock of Alzamend Neuro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Alzamend Neuro is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alzamend Neuro is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Alzamend Neuro has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

About Alzamend Neuro Stock (NASDAQ:ALZN)

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

ALZN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALZN Stock News Headlines

March 26, 2024 | msn.com

ALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024

February 24, 2024 | msn.com

Alzamend Neuro (ALZN) Price Target Increased by 25.00% to 25.50

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

February 13, 2024 | realmoney.thestreet.com

Maxim gets more bearish on Alzamend Neuro, downgrades shares

February 3, 2024 | msn.com

Alzamend Neuro Risks Nasdaq Delisting Over Price Deficiency

December 19, 2023 | markets.businessinsider.com

Buy Rating for Alzamend Neuro Amid Promising Alzheimer’s Drug Trials and Market Potential

December 18, 2023 | msn.com

ALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024

December 18, 2023 | msn.com

ALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

December 11, 2023 | finance.yahoo.com

Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients

December 11, 2023 | finance.yahoo.com

EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year

November 20, 2023 | marketwatch.com

Alzamend Neuro Gets FDA Approval for Trial of Depression Treatment

November 20, 2023 | msn.com

EXCLUSIVE: Alzamend Neuro Receives FDA Go-Ahead Letter For Mid-Stage Major Depressive Disorder Study

November 20, 2023 | finance.yahoo.com

Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients

November 16, 2023 | finance.yahoo.com

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

November 13, 2023 | msn.com

EXCLUSIVE: Alzamend Neuro Seeks FDA Approval For Mid-Stage PTSD Study With Next‑Gen Lithium Therapeutic Drug Candidate

November 13, 2023 | finance.yahoo.com

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001

November 2, 2023 | msn.com

Alzamend Neuro (ALZN) Price Target Increased by 1306.25% to 57.38

October 30, 2023 | benzinga.com

Why Alzamend Neuro (ALZN) Stock Is Nosediving Today

October 30, 2023 | finance.yahoo.com

Alzamend Neuro Announces Reverse Stock Split

October 25, 2023 | finance.yahoo.com

Alzamend Neuro, Inc. (9ZT0.F)

October 23, 2023 | businesswire.com

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001

October 2, 2023 | msn.com

EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder

October 2, 2023 | finance.yahoo.com

Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

September 27, 2023 | seekingalpha.com

Alzamend Neuro CFO Katzoff buys 53K shares

September 26, 2023 | yahoo.com

Rep. Jennifer Wexton Will Not Run for Re-Election After Rare Neurological Disorder Diagnosis

September 22, 2023 | finance.yahoo.com

Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement

See More Headlines

Receive ALZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 9/13/2023
Today: 4/15/2024
Fiscal Year End: 4/30/2024
Next Earnings (Estimated): 7/25/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ALZN
CUSIP: N/A
CIK: 1677077
Web: www.alzamend.com
Phone: 844-722-6303
Fax: N/A
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.9895)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,880,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -612.26%
Return on Assets: -255.65%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.16
Quick Ratio: 0.16

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.47 per share
Price / Book: 1.58

Miscellaneous

Outstanding Shares: 6,870,000
Free Float: 3,281,000
Market Cap: $5.09 million
Optionable: Optionable
Beta: 0.02

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Stephan Jackman (Age 47)
CEO & Director
Comp: $434.24k
Mr. David J. Katzoff (Age 61)
Chief Financial Officer
Comp: $116.67k
Mr. Milton Charles Ault III (Age 54)
Founder & Vice Chairman
Mr. Henry C. W. Nisser Esq. (Age 54)
Executive VP, General Counsel & Director
Comp: $50k
Mr. Kenneth S. Cragun CPA (Age 63)
Senior Vice President of Finance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALZN Stock Analysis - Frequently Asked Questions

How have ALZN shares performed in 2024?: Alzamend Neuro's stock was trading at $0.89 at the beginning of the year. Since then, ALZN stock has decreased by 16.7% and is now trading at $0.7411.
View the best growth stocks for 2024 here.
Are investors shorting Alzamend Neuro?: Alzamend Neuro saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 45,300 shares, a drop of 11.5% from the March 15th total of 51,200 shares. Based on an average trading volume of 54,600 shares, the short-interest ratio is presently 0.8 days. Currently, 0.9% of the shares of the company are short sold.
View Alzamend Neuro's Short Interest.
When is Alzamend Neuro's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024.
View our ALZN earnings forecast.
How were Alzamend Neuro's earnings last quarter?: Alzamend Neuro, Inc. (NASDAQ:ALZN) posted its quarterly earnings results on Wednesday, September, 13th. The company reported ($0.60) earnings per share (EPS) for the quarter.

When did Alzamend Neuro's stock split?: Shares of Alzamend Neuro reverse split on the morning of Tuesday, October 31st 2023. The 1-15 reverse split was announced on Tuesday, October 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
When did Alzamend Neuro IPO?: Alzamend Neuro (ALZN) raised $12 million in an initial public offering (IPO) on Tuesday, June 15th 2021. The company issued 2,500,000 shares at a price of $5.00 per share. Spartan Capital Securities, LLC acted as the underwriter for the IPO and -- was co-manager.
How do I buy shares of Alzamend Neuro?: Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALZN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial